There are currently 695 clinical trials in Orlando, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including AdventHealth Orlando, GSK Investigational Site, Orlando Clinical Research Center and Nemours Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489
Recruiting
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Gender:
All
Ages:
All
Trial Updated:
07/20/2023
Locations: Not set, Orlando, Florida
Conditions: Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Wolman Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency, LIPA Deficiency, LAL-Deficiency
Register for Updates
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265
Recruiting
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Advent Health, Orlando, Florida
Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Register for Updates
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
NCT04983030
Recruiting
A multicenter, randomized, parallel-group, placebo-controlled, double-blind, Phase 1/2a clinical study to investigate the safety, tolerability, immunogenicity and exploratory efficacy of a vaccine regimen consisting of an Ad26.Mos4.HIV prime and a boost with Modified Vaccinia Ankara (MVA)-BN-HIV in combination with broadly neutralizing antibodies (bNAb) PGT121, PGDM1400, and VRC07-523LS in human immunodeficiency virus type 1 (HIV-1)-infected study participants on suppressive anti-retroviral ther... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/29/2023
Locations: Orlando Immunology Center, Orlando, Florida
Conditions: HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Register for Updates
Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia
NCT03576885
Recruiting
Inhaled nitric oxide (iNO) is an effective treatment for pulmonary hypertension (PH) in term and near-term infants. Preterm infants are at risk for early PH that is associated with high risk for bronchopulmonary dysplasia or death. In multiple clinical trials, iNO treatment was not effective for BPD prevention. However, infants were not screened for PH and iNO treatment was not targeted for PH. iNO treatment for PH in preterm infants is controversial due to lack of evidence. The study team hypot... Read More
Gender:
All
Ages:
Between 23 weeks and 29 weeks
Trial Updated:
06/28/2023
Locations: AdventHealth, Orlando, Florida
Conditions: Pulmonary Hypertension, Bronchopulmonary Dysplasia
Register for Updates
Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection
NCT03427346
Recruiting
The study will compare EMR versus ESD technique (both combined with subsequent ablative therapy) of mucosal resection in Barrett's esophagus with regard to efficacy and risk in a long term setting.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/27/2023
Locations: Orlando Health, Orlando, Florida
Conditions: Barrett Esophagus, Barrett Adenocarcinoma, Esophagus Neoplasm
Register for Updates
Study of ALXN2050 in Participants With Hepatic Impairment
NCT05259085
Recruiting
This study will investigate the impact of impaired hepatic function (IHF) on the plasma pharmacokinetics of ALXN2050 in order to provide dosing recommendations for future indications in individuals with varying degrees of IHF.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/22/2023
Locations: Clinical Trial Site, Orlando, Florida
Conditions: Impaired Hepatic Function, Healthy
Register for Updates
Photobiomodulation for Myofascial Pelvic Pain
NCT05926752
Recruiting
The goal of this clinical trial is to evaluate the efficacy of photobiomodulation of the pelvic floor muscles in female Veterans with chronic pelvic pain. The main questions it aims to answer are: Is there a difference in reduction in overall pelvic pain between women who undergo photobiomodulation compared to women who received pelvic floor physical therapy? Is there a difference in compliance with therapy between the two groups? Participants will be randomized to treatment with either 9 treat... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Orlando VA Medical Center, Orlando, Florida
Conditions: Pelvic Pain, Levator Ani Syndrome, Spastic Pelvic Floor Syndrome, Chronic Pelvic Pain Syndrome, Myalgia of Pelvic Floor
Register for Updates
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318
Recruiting
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Orlando Health Cancer Institute, Orlando, Florida
Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Register for Updates
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646
Recruiting
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-17 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 12... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/20/2023
Locations: Arnold Palmer Hospital for Children, Orlando, Florida
Conditions: Chronic Kidney Diseases
Register for Updates
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Recruiting
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term eff... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Orlando Immunology Center (OIC), Orlando, Florida +1 locations
Conditions: HIV Infections, Multi-Antiviral Resistance
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: AdventHealth Medical Group Urology at Orlando, Orlando, Florida +3 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
All
Ages:
Between 1 month and 18 years
Trial Updated:
06/19/2023
Locations: Pediatric Neurology PA, Orlando, Florida
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Register for Updates